Nuvectis Pharma Inc News - NVCT | ADVFN

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma Inc (NVCT) News

Nuvectis Pharma Inc (NVCT)

5.02

0.37

(7.96%)

At close: December 26 4:00PM

Delayed by 15 minutes

5.02

0.00

( 0.00% )

After Hours: 6:14PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

1
Next

gail

gail 1 month ago

grabbed some on the dip

Monksdream

Monksdream 4 months ago

Monksdream

Monksdream 6 months ago

Monksdream

Monksdream 8 months ago

Monksdream

Monksdream 10 months ago

NVCT 10Q due March 6

Monksdream

Monksdream 12 months ago

conix

conix 3 years ago

NVCT HIGHLIGHTS:

*Recently completed Initial Public Offering - $5.00 Per share
*2 Precision Cancer medicines in development - ovarian and triple negative breast
*Data flow throughout 2022
*CEO with multiple success stories in life science sector to $billion dollar market caps
*Analysts project a $66 billion precision medicines market for 2021; In 6 years, this number is expected to top $140 billion

Nuvectis Pharma Inc - Company Background:

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing.

Market Capitalization: $225 million
Range - 52 week: $3.08 - $20.75
Current Price: $20.44
Trades on: Nasdaq Capital Market
Ticker Symbol: NVCT

website: nuvectis.com

TheFinalCD

TheFinalCD 3 years ago

wow from $3 to almost $21

ipo_dude

ipo_dude 3 years ago

TheFinalCD

TheFinalCD 3 years ago

WOW $7 MOVE 3-10

CONGRAT$ NVCT

spindog

spindog 3 years ago

I feel the same

kkballa

kkballa 3 years ago

Nuvectis Pharma

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions